PL 8905
Alternative Names: PL-8905Latest Information Update: 08 Dec 2023
At a glance
- Originator Palatin Technologies
- Class Cyclic peptides; Obesity therapies
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
- No development reported Metabolic disorders